Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration

Abstract

The phase 2 MAHALO clinical trial shows that lampalizumab reduces geographic atrophy secondary to age-related macular degeneration and implicates complement dysregulation in disease pathogenesis.